Denosumab biosimilar (Samsung Bioepis)

地舒单抗生物类似药 (Samsung Bioepis)

Report date: 2026/02/14 20:00:22

Base Information

Drug NameDenosumab biosimilar (Samsung Bioepis)
Drug Alias NameXBRYKOBODENCEOspomyvXbrykSB-16
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionTumor necrosis factor ligand superfamily member 11 inhibitors
TargetsTumor necrosis factor ligand superfamily member 11
Therapy Area/IndicationsGlucocorticoid-induced osteoporosisBone ResorptionOsteoporosis, Postmenopausal +[6] 
Global Approved IndicationsGlucocorticoid-induced osteoporosisBone ResorptionOsteoporosis, Postmenopausal +[6] 
Approved Indications in ChinaN/A
Original Approved Country/TerritoryEU
Original Approved Date2025/02/12
Country/TerritoryUnited StatesPolandFrance +[4] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesSamsung Bioepis Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesBoryungSamsung Bioepis Nl BvSamsung Bioepis Co Ltd
Inactive CompaniesN/A
Active IndicationsGlucocorticoid-induced osteoporosisBone ResorptionOsteoporosis, Postmenopausal +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A